Daniel Margolis, MD, presented “Standardized MRI and Molecular Imaging Reporting for Focal Therapy Follow-up – Creating Imaging Based Short and Intermediate Outcomes” during the 7th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer on September 23, 2023.
This content is available free to the GRU Community. Login or create an account to view it.
How to cite: Margolis, Daniel. “Standardized MRI and Molecular Imaging Reporting for Focal Therapy Follow-up – Creating Imaging Based Short and Intermediate Outcomes.” September 23, 2023. Accessed Aug 2024. https://grandroundsinurology.com/standardized-mri-and-molecular-imaging-reporting-for-focal-therapy-follow-up-creating-imaging-based-short-and-intermediate-outcomes/
Standardized MRI and Molecular Imaging Reporting for Focal Therapy Follow-up – Creating Imaging Based Short and Intermediate Outcomes – Summary
Daniel Margolis, MD, focuses on standardized MRI and molecular imaging reporting for follow-up in prostate cancer focal therapy. Implementing standardized protocols for imaging evaluation post-focal therapy aims to ensure consistency and reliability across different healthcare settings, facilitate accurate comparison of treatment outcomes, and enable evidence-based decision-making.
Multiparametric MRI (mpMRI) is a cornerstone of the follow-up strategy. By utilizing standardized reporting systems such as the Prostate Imaging Reporting and Data System (PI-RADS), radiologists can systematically assess post-treatment changes, detect residual or recurrent disease, and monitor treatment response. Dr. Margolis also discusses molecular imaging techniques that offer additional insights into treatment response and disease activity at a molecular level. Novel tracers and imaging agents target specific biological markers associated with prostate cancer, enhancing the precision and sensitivity of post-treatment assessments.
Dr. Margolis emphasizes the importance of integrating these imaging modalities into a cohesive framework. This approach not only aids in the early detection of treatment failure or disease recurrence but also guides timely intervention and adjustment of therapeutic strategies.
The Global Summit on Precision Diagnosis and Treatment of Prostate Cancer is a unique multi-disciplinary forum organized to inform the key health care stakeholders about the emerging advances in clinical case and research and create a consensus-based vision for the future of precision care and educational and research strategy for its realization. The mission of the Summit is to fill the currently existing gap between the key experts of in vivo imaging, the world authorities in the in vitro fluid- and tissue-based molecular diagnostics, including genomics, and thought leaders in the development of novel observation strategies (e.g., active surveillance, or AS) and therapeutic interventions.
ABOUT THE AUTHOR
Daniel Margolis, MD, is an Associate Professor of Radiology at Weill Cornell Medicine in New York City. He is a graduate of the University of California, Berkeley, and earned his MD from the University of Southern California in Los Angeles. After a transitional year-long internship with the Los Angeles VA Healthcare System, he completed a residency in Diagnostic Radiology at the University of California, Los Angeles. Dr. Margolis completed a Fellowship in Advanced Imaging at Stanford University Medical Center and the K30 Graduate Training Program in Translational Investigation at UCLA. He has 90+ publications regarding using MRI for detecting and characterizing prostate cancer. He serves on the American College of Radiology Prostate Imaging Reporting and Data Systems Committee and is Co-Chair of the Society of Abdominal Radiology Prostate Cancer Disease-Focused Panel.
